Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor/Tezacaftor/Ivacaftor (Kaftrio)
The introduction of Cystic Fibrosis Trans Regulatory modulator (CFTRm) drugs has seen a transformation in Cystic Fibrosis (CF) treatment. This has led to a significant improvement in lung function and quality of life with the potential for a real impact on life expectancy.Transient mild to moderate...
Guardado en:
Autores principales: | Mahan Salehi, Mubashar Iqbal, Asha Dube, Amer AlJoudeh, Frank Edenborough |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/82aa5a8243be4feda1590e50d4520ca0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Long-Term Outcomes in Real Life of Lumacaftor–Ivacaftor Treatment in Adolescents With Cystic Fibrosis
por: Stéphanie Bui, et al.
Publicado: (2021) -
Urticaria multiforme-like eruption due to a novel agent elexacaftor/tezacaftor/ivacaftor in a pediatric patient with cystic fibrosis
por: Rebecca H. Goldberg, BS, et al.
Publicado: (2021) -
Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment
por: Ciaran A. Shaughnessy, et al.
Publicado: (2021) -
XV-2c and KM: 19 haplotype analysis in Chilean patients with cystic fibrosis and unknown CFTR gene mutations
por: REPETTO,GABRIELA M, et al.
Publicado: (2007) -
Impact of Airway Inflammation on the Efficacy of CFTR Modulators
por: Carla M. P. Ribeiro, et al.
Publicado: (2021)